Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

SAN FRANCISCO, Oct. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced interim data from its multi-center, open-label Phase 2a clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients hospitalized for acute heart failure.

-- Statistically significant reduction in pulmonary capillary wedge

pressure

-- Statistically significant increase in diuresis

-- Trend toward reduction in right atrial pressure

-- Trend toward increase in cardiac output

-- No hypotension

-- No change in serum creatinine

About the Study

The objective of the Phase 2a study is to assess hemodynamic and renal effects of CD-NP in patients with acute heart failure. In this dose escalation trial, stabilized acute heart failure patients receiving standard-of-care heart failure medications were administered an 8-hour infusion of CD-NP at 3 ng/kg/min (n=11), followed by a 14-hour washout period, and then an 8-hour infusion of CD-NP at 10 ng/kg/min (n=9).

Effects on Hemodynamics

Results from the first cohort of patients show a statistically significant reduction in pulmonary capillary wedge pressure (PCWP). Infusion with 3 ng/kg/min of CD-NP resulted in a statistically significant reduction of 2.9 mmHg relative to baseline at eight hours (p=0.02). Infusion of 10 ng/kg/min CD-NP following a washout period resulted in a further reduction of PCWP, which reached statistical significance at two hours after initiation (p=0.02). In patients who completed both doses of CD-NP, there was a statistically significant overall reduction in PCWP of 5.4 mmHg (p=0.002) from the initial baseline PCWP of 23.7 mmHg. The interim results also include an observed tre
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... have made great strides in saving China,s endangered national ... over 65 giant panda reserves that have been established ... just 1596 pandas remain in the wild. , ... save the panda by improving genetic diversity, avoid inbreeding ... how are these high-profile programs doing so far? , ...
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
(Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership with ... data management solutions for clinical trials. The company launched ... data capture (EDC) and clinical data management. Formedix, a ... added TrialMaster to its Transform for EDC product line. ... TrialMaster, is being released this week, in response to ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... PAREXEL International (NASDAQ: PRXL ), a ... H. von Rickenbach, Chairman and Chief Executive Officer of ... Massachusetts Biotechnology Council (MassBio) CRO/CMO Symposium , to ... Waltham, Massachusetts. The symposium, organized by the MassBio Contract ...
... Study results published today in the   New - ...   show that 3-year graft survival is significantly greater in all ...   Kidney Transporter compared to those stored in a traditional box ... [1]   The graft survival difference at three years was ...
... Graduate Institute (KGI) has been selected by the Council ... Foundation to administer the Professional Science Master,s (PSM) Affiliation ... quality standards for PSM programs across the country. ... look forward to providing leadership for this important degree ...
Cached Biology Technology:PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 2PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 3PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 4PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 5Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 2Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 3KGI Selected to Administer PSM Affiliation Process 2
(Date:7/23/2014)... Networking in personalized cancer medicine, (the WIN consortium), recently ... Thomas Jefferson University will be one of its ... prestigious group in the Tri-State Area. The goal of ... medicine to the patient by forging collaborations between partners ... in the WIN consortium means Jefferson cancer patients will ...
(Date:7/23/2014)... temperature around the world by 2050, according to one ... Climate Change (IPCC), may be advantageous to the physiology ... growth of forage plants such as Stylosanthes capitata ... tropical countries such as Brazil., The conclusion is from ... of Biology at the Ribeiro Preto Faculty of Philosophy, ...
(Date:7/23/2014)... HOLE, MA -- What do mollusks, starfish, and ... marine habitat, they are all calcifiersorganisms that use ... skeletons and shells for stability and protection. , ... , published by the Marine Biological Laboratory, addresses ... composition changes worldwide. , As atmospheric carbon dioxide ...
Breaking Biology News(10 mins):New partnership brings more personalized cancer treatment to Philadelphia 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2
... Fingerprints mark us out as individuals and leave telltale ... touch, but what are fingerprints really for? According to ... and tree-climbing koalas have fingerprints and some South American ... everyone presumed that fingerprints are there to help us ...
... in a remote region of the Russian mountains a previously ... discovered. Lead Scientist Professor Hans Cornelissen and his Russian-Dutch team ... The root belongs to the small alpine plant Corydalis conorhiza ... upward through layers of snow. Given this novel behaviour, the ...
... edition of the BBVA Foundation Frontiers of Knowledge ... under the presidency of the Spanish Minister of ... Foundation President, Francisco Gonzlez. The public at the ... scientific community and high-level government institutions alongside personalities ...
Cached Biology News:Urban myth disproved: Fingerprints do not improve grip friction 2Newly discovered snow roots are 'evolutionary phenomenon' 2The BBVA Foundation presents its Frontiers of Knowledge Awards 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... exist between the various commercial and lab-prepared ... used, the length and GC content of ... manufacturing protocol employed all influence the optimal ... With all the different variables to consider, ...
... ICS-1500 system provides excellent performance with ... electrolytic suppression, and column heater all ... outstanding sensitivity and stability. The vacuum ... for trace-level work. Operate in manual ...
Biology Products: